Ubenimex capsule improves general performance and chemotherapy related toxicity in advanced gastric cancer cases.
To evaluate the effect of ubenimex capsule on general performance and chemotherapy related toxicity in patients with advanced gastric cancer undergoing chemotherapy. Patients with advanced gastric cancer were randomly divided into two groups: with or without ubenimex. All received the following regimen for 2 cycles: docetaxel 40mg/m(2) intravenous infusion on days 1 and 8, cisplatin 15mg/m(2) and tegafur 600mg/m(2) intravenous infusion from days 1 to 5. Oral ubenimex capsule at 30mg daily was continued for 8 weeks from the start of chemotherapy. Study targets included Karnofsky performance status (KPS), body weight, leukocytes, hemoglobin, variation of several immunologic index prior,during and after chemotherapy. Sixty-three patients were recruited into this study, 32 randomly entered into the ubenimex capsule and 31 into the control group. KPS score and body weight after chemotherapy were more stable in the treatment group (P <0.05), and myelosuppression, including reduction of leukocytes, hemoglobin and platelets, was milder (P <0.05). T lymphocytes (CD3 +), T assisted- induced lymphocytes (CD3 +, CD4 +), T suppressor and NK cells (CD16 +, CD56 +) all increased after ubenimex capsule intake, while decreasing in the control group (P <0.05). Ubenimex capsule could improve general performance and reduce chemotherapy related toxicity in patients with advanced gastric cancer.